This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: December 3, 2007
Last updated: October 1, 2008
Last verified: October 2008
The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.

Condition Intervention Phase
Schizophrenia Drug: PF-3463275 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in the CNS Vital Signs Cognition Battery composite score [ Time Frame: 6 days ]
  • Safety Endpoints: tolerability, laboratory tests, vital signs, and ECG's. [ Time Frame: 38 days ]
  • Pharmacokinetics of PF-3463275 [ Time Frame: 6 days ]

Secondary Outcome Measures:
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: 6 days ]
  • Change from baseline in the CNS Vital Signs Cognition Battery domain scores [ Time Frame: 6 days ]

Enrollment: 36
Study Start Date: November 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: PF-3463275
PF-3463275 10mg
Experimental: 2 Drug: PF-3463275
PF-3463275 25mg
Placebo Comparator: 3 Drug: Placebo


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months
  • Stable symptoms of schizophrenia for at least 3 months.

Exclusion Criteria:

  • Subjects with a psychiatric disorder other than schizophrenia
  • Substance dependence or abuse
  • Women who have child bearing potential.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00567203

United States, California
Pfizer Investigational Site
Glendale, California, United States, 91206
United States, New Jersey
Pfizer Investigational Site
Willingboro, New Jersey, United States, 08046
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trials Disclosure Group, Pfizer, Inc. Identifier: NCT00567203     History of Changes
Other Study ID Numbers: A9131004
Study First Received: December 3, 2007
Last Updated: October 1, 2008

Additional relevant MeSH terms:
Cognition Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Neurocognitive Disorders processed this record on August 17, 2017